Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial Juan Antonio García-Velasco, Sanja.

Slides:

Advertisements

Similar presentations

Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis Sesh Kamal Sunkara, Jyotsna Pundir,

Advertisements

Modified natural cycle IVF and mild IVF: a 10 year Swedish experience

Blastocyst-stage versus cleavage-stage embryo transfer in women with high oestradiol concentrations: randomized controlled trial Eman A. Elgindy, Ahmed.

Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase TG Lainas, IA Sfontouris, IZ Zorzovilis, GK Petsas,

J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casañ, F

J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casañ, F

Double GnRH-antagonist dose before HCG administration may prevent OHSS in oocyte-donor cycles: a pilot study Yannis Prapas, Ioannis Panagiotidis, Ioannis.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

HP-HMG versus rFSH in treatments combining fresh and frozen IVF cycles: success rates and economic evaluation Jaro Wex-Wechowski, Ahmed M. Abou-Setta,

Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response William L. Ledger, Bart C.J.M. Fauser, Paul.

Mid-luteal progesterone concentrations are associated with live birth rates during ovulation induction J.-C. Arce, A. Balen, P. Platteau, G. Pettersson,

Higher β-HCG concentrations and higher birthweights ensue from single vitrified embryo transfers Kevin N. Keane, Kamarul Bahyah Mustafa, Peter Hinchliffe,

Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study A.Z. Isik, G.S. Caglar, E. Sozen,

Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF Bart C.J.M. Fauser, Michael.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating.

No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH George Griesinger, Daniel B. Shapiro, Efstratios.

Clinical utility of newly developed highly purified human menopausal gonadotrophins: a randomized controlled trial Hwa Seon Koo, Hwang Kwon, Doo Seok.

Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist- treated oocyte donors Nikolaos P. Polyzos, Dominic Stoop, Christophe.

Oestradiol valerate pretreatment in GnRH-antagonist cycles: a randomized controlled trial Christophe Blockeel, Sara Engels, Michel De Vos, Patrick Haentjens,

Jacob Farhi, Onit Sapir, Maor Maman, Benjamin Fisch, Avi Ben-Haroush

Circulating concentration of stem cell factor in serum of stimulated IVF patients Ali Salmassi, Sandy Zorn, Liselotte Mettler, Kerstin Koch, Walter Jonat,

Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol) Yanping Kuang, Qiuju Chen,

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

Fresh transfer outcome predicts the success of a subsequent frozen transfer utilizing blastocysts of the same cohort L.F. Doherty, J.R. Martin, U. Kayisli,

New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation Giovanna Sighinolfi,

Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective.

Short-term, low-dose, non-steroidal anti-inflammatory drug application diminishes premature ovulation in natural-cycle IVF Satoshi Kawachiya, Tsunekazu.

Maternal concentrations of human chorionic gonadotrophin in very early IVF pregnancies and duration of pregnancy: a follow-up study Tom G. Tanbo, Manuela.

Novel aspects of the endocrinology of the menstrual cycle

Sarah McCredie, William Ledger, Christos A. Venetis

Ongoing pregnancies from early retrieval of prematurely developing antral follicles after DHEA supplementation Murat Sönmezer, Aylin Pelin Çil, Kutluk.

Effect of energy expenditure and physical activity on the outcomes of assisted reproduction treatment Mert Kucuk, Fadime Doymaz, Bulent Urman Reproductive.

Oocyte vitrification in the 21st century and post-warming fertility outcomes: a systematic review and meta-analysis Neelam Potdar, Tarek A Gelbaya, Luciano.

Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa F. Olivennes, G. Trew,

Sequential use of letrozole and gonadotrophin in women with poor ovarian reserve: a randomized controlled trial Vivian Chi Yan Lee, Carina Chi Wai Chan,

Jyotsna Pundir, Sesh Kamal Sunkara, Tarek El-Toukhy, Yacoub Khalaf

Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen–thawed embryo transfer: a randomized study Ariel Weissman, Eran Horowitz,

Ronit Machtinger, Raoul Orvieto Reproductive BioMedicine Online

Follicular flushing in natural cycle IVF does not affect the luteal phase – a prospective controlled study M. von Wolff, A. Kohl Schwartz, P. Stute,

Male age negatively influences clinical pregnancy rate in women younger than 40 years undergoing donor insemination cycles Su-Ann Koh, Katherine Sanders,

Donor information considered important to donors, recipients and offspring: an Australian perspective I.S. Rodino, P.J. Burton, K.A. Sanders Reproductive.

Impact of vitamin D levels on ovarian reserve and ovarian response to ovarian stimulation in oocyte donors Alberta Maria Fabris, Maria Cruz, Carlos Iglesias,

Mid-follicular LH supplementation in women aged 35–39 years undergoing ICSI cycles: a randomized controlled study R Matorras, B Prieto, A Exposito, R.

A unique biological in-vivo model to evaluate follicular development during in-vitro maturation treatment S.E. Elizur, W.Y. Son, H. Clarke, D. Morris,

Michael J. Levy, William Ledger, Efstratios M. Kolibianakis, Pieta C

Intra-cycle variation of the uterine cavity indentation assessed with three-dimensional ultrasound in natural and stimulated cycles Sotirios H. Saravelos,

Double GnRH-antagonist dose before HCG administration may prevent OHSS in oocyte-donor cycles: a pilot study Yannis Prapas, Ioannis Panagiotidis, Ioannis.

LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles Kevin Doody, Paul Devroey, Keith Gordon, Han Witjes, Bernadette Mannaerts

Mohamed A. Aboulghar, Heba Marie, Yahia M. Amin, Mona M

Low-dose HCG may improve pregnancy rates and lower OHSS in antagonist cycles: a meta-analysis IP Kosmas, K Zikopoulos, I Georgiou, E Paraskevaidis, C.

S. Seshadri, S.K. Sunkara, Y. Khalaf, T. El-Toukhy, H. Hamoda

Does ovarian stimulation regimen affect IVF outcome

Should we be promoting embryo transfer at blastocyst stage?

Anna Pia Ferraretti, Paul Devroey, M. Cristina Magli, Luca Gianaroli

GnRH antagonist pre-treatment: one centre's experience for IVF–ICSI cycle scheduling Veronique Viardot-Foucault, Sadhana Nadarajah, Weng Kit Lye, Heng.

Pietro Gambadauro, Ramesan Navaratnarajah

Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature Micah J. Hill, Gary Levy, Eric D. Levens

Testosterone concentrations in early pregnancy: relation to method of conception in an infertile population Ruth B. Lathi, Sharon E. Moayeri, Charitha.

Cryopreserved embryo transfer: adjacent or non-adjacent to failed fresh long GnRH- agonist protocol IVF cycle Alexander Volodarsky-Perel, Talia Eldar-Geva,

Ovarian reserve screening before contraception?

Live birth following early follicular phase oocyte collection and vitrified-warmed embryo transfer 8 days later Safak Hatırnaz, Ebru Hatırnaz, Baris.

Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone.

C. Yding Andersen, K. Vilbour Andersen Reproductive BioMedicine Online

Randomized controlled trial of benzocaine versus placebo spray for pain relief at hysterosalpingogram E.A. Bachman, S. Senapati, M.D. Sammel, S.K. Kalra

John Yovich, James Stanger, Peter Hinchliffe

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: a prospective, clinical feasibility study Georg Griesinger, Henriette.

Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial Ernesto Bosch, Jon Havelock, Fernando Sánchez.

Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Antonio La Marca, Martina Capuzzo Reproductive.

Presentation transcript:

Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial Juan Antonio García-Velasco, Sanja Kupesic, Antonio Pellicer, Claire Bourgain, Carlos Simón, Milan Mrazek, Paul Devroey, Joan-Carles Arce Reproductive BioMedicine Online Volume 24, Issue 2, Pages 153-162 (February 2012) DOI: 10.1016/j.rbmo.2011.10.016 Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

Figure 1 Overview of the gonadotrophin-releasing hormone (GnRH) antagonist treatment regimens for oocyte donors. (A) Degarelix starting in the mid-luteal phase. (B) Degarelix starting in the early follicular phase. (C) Ganirelix starting in the mid-follicular phase. HCG=human chorionic gonadotrophin; HP-HMG=highly purified human menopausal gonadotrophin; OR=oocyte retrieval; P4=progesterone. Reproductive BioMedicine Online 2012 24, 153-162DOI: (10.1016/j.rbmo.2011.10.016) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

Figure 2 Study flow chart of the oocyte donors. GnRH=gonadotrophin-releasing hormone; ITT=intention to treat. Reproductive BioMedicine Online 2012 24, 153-162DOI: (10.1016/j.rbmo.2011.10.016) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

Figure 3 Individual coefficients of variation of follicular size at screening on day 3±1 of the natural cycle and on stimulation day 1 in oocyte donors treated with placebo (n=39) (A) or GnRH antagonist (n=39) (B) in the mid-luteal phase of the natural cycle (the degarelix-ML group). The horizontal dashed line displays the 75th percentile (47.1%) of the whole trial population at screening. Reproductive BioMedicine Online 2012 24, 153-162DOI: (10.1016/j.rbmo.2011.10.016) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions